Loading…
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $63M | $-189M | $-205M | $-182M | -66.9% | 699.0% | -64.0% |
| 2024 | $8M | $-567M | $-568M | $-131M | -122.5% | - | 649.2% |
| 2023 | $0M | $-76M | $-76M | $-68M | -12.5% | - | -27.3% |
| 2022 | $0M | $-120M | $-104M | $-96M | -15.9% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 7.87 | 62.90 |
| Operating Revenue | - | 0 | 0 | 7.87 | 62.90 |
| Cost Of Revenue | - | - | 0 | 7.08 | 9.30 |
| Gross Profit | - | - | 0 | 0.80 | 53.60 |
| Operating Expense | - | 119.73 | 99.82 | 168.35 | 266.67 |
| Research And Development | - | 87.82 | 71.29 | 99.12 | 115.11 |
| Selling General And Administration | - | 31.92 | 28.53 | 69.23 | 151.56 |
| Total Expenses | - | 119.73 | 99.82 | 175.43 | 275.97 |
| Operating Income | - | -119.73 | -99.82 | -167.56 | -213.06 |
| Total Operating Income As Reported | - | -119.73 | -99.82 | -592.63 | -213.06 |
| EBITDA | - | -119.54 | -75.58 | -566.92 | -189.21 |
| Normalized EBITDA | - | -128.49 | -75.94 | -140.90 | -188.37 |
| EBIT | - | -119.73 | -75.80 | -567.60 | -190.94 |
| Interest Income | - | 7.45 | 24.61 | 27.06 | 21.43 |
| Interest Expense | - | - | 0 | 0.34 | 13.68 |
| Net Interest Income | - | 7.45 | 24.61 | 26.72 | 7.75 |
| Other Non Operating Income Expenses | - | -0.87 | -0.95 | -1.08 | 1.53 |
| Other Income Expense | - | 8.09 | -0.59 | -427.10 | 0.69 |
| Interest Income Non Operating | - | 7.45 | 24.61 | 27.06 | 21.43 |
| Interest Expense Non Operating | - | - | 0 | 0.34 | 13.68 |
| Net Non Operating Interest Income Expense | - | 7.45 | 24.61 | 26.72 | 7.75 |
| Pretax Income | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Net Income From Continuing And Discontinued Operation | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Net Income From Continuing Operation Net Minority Interest | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Net Income | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Net Income Common Stockholders | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Net Income Including Noncontrolling Interests | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Normalized Income | - | -113.16 | -76.16 | -141.92 | -203.79 |
| Diluted NI Availto Com Stockholders | - | -104.20 | -75.80 | -567.94 | -204.63 |
| Basic Average Shares | 197.89 | 216.72 | 218.88 | 268.77 | - |
| Diluted Average Shares | 197.89 | 216.72 | 218.88 | 268.77 | - |
| Reconciled Depreciation | - | 0.20 | 0.22 | 0.68 | 1.74 |
| Reconciled Cost Of Revenue | - | - | 0 | 7.08 | 9.30 |
| Total Unusual Items | - | 8.96 | 0.36 | -426.02 | -0.84 |
| Total Unusual Items Excluding Goodwill | - | 8.96 | 0.36 | -426.02 | -0.84 |
| Special Income Charges | - | - | 0 | -425.07 | -0.03 |
| Other Special Charges | - | - | - | 425.07 | - |
| Gain On Sale Of Security | - | 8.96 | 0.36 | -0.95 | -0.81 |
| General And Administrative Expense | 24.28 | 31.92 | 28.53 | - | - |
| Other Gand A | 24.28 | 31.92 | 28.53 | - | - |
| Gain On Sale Of Ppe | - | - | - | 0 | -0.03 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Nuvation Bio Inc.this co. | NUVB | $1.8B | -8.80 | 5.89 | -66.9% | -8.95 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B | -14.08 | 8.67 | -61.6% | -13.48 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL | $1.8B |
| - |
| - |
| - |
| - |
| 110.33 |
| 5.14 |
| 4.7% |
| 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Rapport Therapeutics, Inc. | RAPP | $1.8B | - | -178.20 | -23.0% | - |
| Surgery Partners, Inc. | SGRY | $1.8B | -22.97 | 1.04 | -4.5% | 9.86 |
| SELLAS Life Sciences Group, Inc. | SLS | $1.8B | -66.17 | 25.08 | -37.9% | -60.37 |
| Peer Median | - | -5.34 | 3.22 | -13.8% | 7.64 | |